共 50 条
DNA methylation inhibitors: Retrospective and perspective view
被引:20
|作者:
Uddin, Md Gias
[1
,2
]
Fandy, Tamer E.
[1
]
机构:
[1] Univ Charleston, Sch Pharm, Dept Pharmaceut & Adm Sci, Charleston, WV 29403 USA
[2] Appalachian Coll Pharm, Dept Pharmaceut Sci, Oakwood, VA 24631 USA
来源:
ADVANCES IN CANCER RESEARCH, VOL 152
|
2021年
/
152卷
关键词:
CATECHOL-O-METHYLTRANSFERASE;
TUMOR-SUPPRESSOR GENES;
GREEN TEA POLYPHENOLS;
DE-NOVO METHYLATION;
HISTONE DEACETYLASE;
SILENCED GENES;
CANCER CELLS;
PHASE-I;
5-AZACYTIDINE;
REACTIVATION;
D O I:
10.1016/bs.acr.2021.03.007
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
DNA methylation is an epigenetic modification that contributes to essential biological processes such as retrotransposon silencing, cell differentiation, genomic imprinting and X-chromosome inactivation. DNA methylation generates a stable epigenetic mark associated with silencing of gene expression. Aberrant DNA methylation is associated with the development of different tumor types. Reversing DNA methylation is a rational strategy to restore gene re-expression and induce cell differentiation in cancer. DNA hypomethylating agents is a class of drugs that demonstrated efficacy in different tumors. In this chapter, the classification of DNA hypomethylating agents, their pharmacodynamics and their potential drawbacks will be discussed.
引用
收藏
页码:205 / 223
页数:19
相关论文